8-K: VolitionRx Announces Fiscal Year 2024 Results: Revenue Up, Focus Shifts to Licensing Deals

VolitionRx reports increased revenue for fiscal year 2024, driven by Nu.Q Vet Cancer Test sales, and outlines its strategy to secure licensing deals in the human diagnostics market.

Summary

• VolitionRx Limited announced its financial results and business updates for the fourth quarter and full fiscal year ended December 31, 2024.
• The company's revenue for 2024 was $1.2 million, a 59% increase compared to the previous year.
• Nu.Q Vet revenue increased by 75%, and Nu.Q Discover revenue increased by 40% compared to 2023.
• Operating expenses decreased by 23% year-over-year due to cost reduction measures.
• Cash and cash equivalents totaled approximately $3.3 million as of December 31, 2024.
• Subsequent to year-end, VolitionRx received $1.8 million in non-dilutive funding from Belgian institutions and raised approximately $2.3 million in a registered direct offering.
• The company aims to achieve cash neutrality in 2025, where income matches expenditure on a cash basis.
• VolitionRx sold approximately 120,000 Nu.Q Vet Cancer Tests in 2024.
• The Nu.Q Vet Cancer Test is now available in over 20 countries worldwide.
• The company is focused on securing multiple licensing deals for human indications in 2025.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to revenue growth, cost reduction, and progress in securing licensing deals. However, the relatively low cash balance and the need to secure licensing agreements for future growth temper the overall optimism.

Positives

• Revenue increased by 59% to $1.2 million in 2024.
• Nu.Q Vet revenue increased by 75%.
• Nu.Q Discover revenue increased by 40%.
• Operating expenses decreased by 23% due to cost reduction measures.
• The company sold approximately 120,000 Nu.Q Vet Cancer Tests in 2024.
• VolitionRx received $1.8 million in non-dilutive funding from Belgian institutions after year-end.
• The company raised approximately $2.3 million in a registered direct offering after year-end.
• The Nu.Q Vet Cancer Test is now available in over 20 countries worldwide.
• The company is focused on securing multiple licensing deals for human indications in 2025.

Negatives

• Cash and cash equivalents totaled approximately $3.3 million as of December 31, 2024, which may be considered low for a company pursuing multiple licensing deals.

Risks

• The company's ability to achieve cash neutrality in 2025 depends on securing licensing receipts.
• The company's success depends on the acceptance of its products in the marketplace.
• The company faces fierce competition in the diagnostics and disease monitoring market.
• The company's ability to secure adequate intellectual property protection is a risk.

Future Outlook

VolitionRx aims to sign multiple licensing deals for human indications in 2025 and achieve cash neutrality, meaning income, including licensing receipts, matches expenditure on a cash basis.

Management Comments

• Cameron Reynolds, President and Group Chief Executive Officer, stated that the focus in 2024 was on generating sufficient clinical data to convince major players in the diagnostic, screening, and liquid biopsy world that the Nu.Q platform will play a significant role in the oncology and sepsis markets.
• Reynolds believes this was achieved beyond expectations and that 2025 is about signing multiple licensing deals for human indications.
• Reynolds looks forward to sharing more progress in the coming months.

Industry Context

VolitionRx is positioning itself in the growing epigenetics-based diagnostics market, targeting both oncology and sepsis. The company's strategy involves securing licensing deals with larger players in the human diagnostic and liquid biopsy space, which are multibillion-dollar markets.

Comparison to Industry Standards

• It is difficult to compare VolitionRx directly to industry standards without knowing the specific details of their technology and target markets.
• However, companies like Exact Sciences (EXAS) in cancer diagnostics and bioMérieux in sepsis diagnostics are potential benchmarks for market penetration and licensing strategies.
• The success of VolitionRx will depend on the clinical validation of its Nu.Q platform and its ability to secure favorable licensing agreements.

Management Changes

Stakeholder Impact

• Shareholders: The increased revenue and focus on licensing deals could positively impact shareholder value.
• Employees: The company's cost reduction measures may have impacted employees.
• Customers: The expanded availability of the Nu.Q Vet Cancer Test benefits veterinary professionals and pet owners.
• Suppliers: Potential licensing deals could lead to increased demand for VolitionRx's products and services.

Next Steps

• VolitionRx will host a conference call on March 31, 2025, to discuss the financial results and business update.
• The company aims to sign multiple licensing deals for human indications in 2025.
• The company aims to achieve cash neutrality in 2025.

Key Dates

Keywords

VolitionRx, Nu.Q, epigenetics, cancer, sepsis, diagnostics, licensing, financial results, revenue, veterinary, oncology, NETosis